Biocon News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon from all sources in a single place.

29 Jul 2026, 12:02PM

431.10

-0.31%

Biocon gets Canadian health regulator's nod for Yesintek autoinjector pen

Business Standard

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

29 Jul 2026, 08:33AM

431.10

-0.31%

Company Update

Biocon Ltd - 532523 - Company Statement

BSE India

Company Statement

pdf

Biocon Ltd.

28 Jul 2026, 08:05PM

431.10

-0.31%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Earnings Conference call for Analysts and Investors

pdf

Biocon Ltd.

28 Jul 2026, 08:01PM

431.10

-0.31%

Board Meeting

Biocon Ltd - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Earnings …

BSE India

Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors

pdf

Biocon Ltd.

22 Jul 2026

431.10

-0.31%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Completion of tenure of Independent Director

pdf

Biocon Ltd.

22 Jul 2026

431.10

-0.31%

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

Business Standard

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.